Enzalutamide reduces skeletal-related events in men with advanced castration-resistant prostate cancer
the ONA take:
According to a new study published in the journal Lancet Oncology, enzalutamide was found to decrease the risk of skeletal-related events, including radiotherapy to the bone and spinal cord compression, in men with metastatic castration-resistant prostate cancer (mCRPC). In addition, enzalutamide lowered pain and increased quality of life.
In the phase 3 AFFIRM study, patients with mCRPC whose disease progressed on or after docetaxel either took enzalutamide, an androgen receptor, by mouth once daily or placebo. Researchers found that enzalutamide decreased the risk of skeletal-related events by 31% compared with placebo (P=0.0001), and the duration to first skeletal-related event was 16.7 months for patients who took enzalutamide versus 13.3 months for those who took placebo (P=0.0001).
Furthermore, enzalutamide decreased pain severity (P<0.0001) and risk of pain progression (P=0.0018). Patients on enzalutamide experienced health-related quality of life (HRQoL) deterioration after 9.0 months, while those on placebo had HRQoL deterioration in 3.7 months (P<0.0001).
Xtandi (enzalutamide) was initially approved by the U.S. Food and Drug Administration (FDA) in 2012, and the FDA recently approved enzalutamide as first-line therapy for men with mCRPC.
Enzalutamide was found to decrease the risk of skeletal-related events in mCRPC.
Enzalutamide (XTANDI™) reduces the risk of skeletal-related events compared with placebo, as well as reducing pain and increasing quality of life in men with metastatic castration-resistant prostate cancer (mCRPC) according to new results from the AFFIRM study published in Lancet Oncology.
Bone is the most common site of spread in prostate cancer, accounting for about 90% of metastases, resulting in some of the most painful and functionally compromising complications of the disease.
Professor Johann De Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research London, and Head of the Drug Development Unit at The Royal Marsden NHS Foundation Trust, comments: "These quality of life data endorse the fact that enzalutamide is a major advance in the treatment of prostate cancer."
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|